Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: 0.00 (0.00%)
Spread: 0.50 (3.704%)
Open: 13.75
High: 13.75
Low: 13.75
Prev. Close: 13.75
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Portfolio Company Announces Strengthening Sales

24 Oct 2011 07:00

RNS Number : 6687Q
Angle PLC
24 October 2011
 



For immediate release

24 October 2011

 

ANGLE plc

 

("ANGLE" or the "Company")

 

PORTFOLIO COMPANY GEOMERICS ANNOUNCES STRENGTHENING SALES

 

 

ANGLE plc, which focuses on the commercialisation of technology, is pleased to announce that its 33% owned portfolio company Geomerics, which specialises in computer games middleware, has made significant progress on a number of fronts.

 

Sales continue to grow at an encouraging rate. Geomerics' Enlighten technology is now being employed in 18 titles worldwide and is currently in evaluation and under consideration for many more. Among these titles are two of the most hotly anticipated games of 2011. Battlefield 3, from EA DICE, is released on 28th October. It is considered a challenger to Call of Duty's market dominance. The game has been backed by a $100m marketing campaign and has received high praise and multiple awards for the quality of its graphics, of which the lighting is driven by Geomerics' Enlighten engine. Battlefield 3 is followed by the release of Need for Speed: The Run on 18th November. This is the next game in one of the most successful franchises of all time and is built on the same Enlighten technology as Battlefield 3.

 

Geomerics is also delighted that it has secured its first deal inside Korea, which will see Enlighten used in multiple titles. This opens up a whole new market for Enlighten and, on the back of sales in Japan, demonstrates that Geomerics is on its way to establishing a strong base in the Asian market.

 

Geomerics' participation in Epic Games' prestigious Unreal Engine 3 Integrated Partners Programme continues to go well and is yielding a range of new sales opportunities.

 

Finally, Geomerics has been awarded new grant funding to research applications of its technology on mobile devices. Geomerics will receive €470,000 over the next three years as part of a €2.8 million EU-funded project researching the next generation of graphics technology for mobile platforms.

 

 

 

Chris Doran, Founder of Geomerics, commented:

"At Geomerics we have tracked the rise in performance of mobile platforms very closely. It is clear that they are fast approaching console performance, and at the high end will overtake this in 2012. We are very excited about the prospect of taking our console technology to mobile platforms, and to contributing to joint R&D on the future direction of graphics technology for mobile devices."

 

 

Andrew Newland, Chief Executive of ANGLE commented:

"We are very pleased with the Geomerics' continued strong progress and look forward to the positive market impact when Battlefield 3 launches at the end of this week."

 

 

 

 

 

For further information:

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 

Collins Stewart Europe Limited

Matt Goode

 

0207 523 8325

Buchanan

Lisa Baderoon

 

0207 466 5000

Scott Harris

Stephen Scott, Harry Dee

 

0207 653 0030

 

 

About Geomerics www.geomerics.com

 

Geomerics is an innovation-led company developing cutting-edge graphics technology for the games industry. Based in Cambridge, UK, Geomerics has built a team that combines world-class management and games industry experience with some of the UK's leading researchers. Geomerics launched its groundbreaking Enlighten technology in 2009. Enlighten redefines how designers use and control lighting within a game.

 

Geomerics partners with many of the leading companies in the games industry and is currently working with developers around the world on AAA titles for release in 2011 and 2012. The first titles incorporating Enlighten include the highly anticipated 'Battlefield 3' and 'Need for Speed: The Run'.

 

For more details about Geomerics research into mobile platforms, visit www.lpgpu.org 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRBDGLBDBGBX
Date   Source Headline
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories
4th Mar 20217:00 amRNSUpdate on submission for FDA clearance
18th Feb 20217:00 amRNSParsortix-harvested CTCs uncover novel biomarker
8th Feb 20217:00 amRNSParsortix: Dynamic assessment of patient response
29th Jan 20217:00 amRNSParsortix demonstrates high capture rate of CTCs
26th Jan 20211:00 pmRNSHolding(s) in Company
20th Jan 20217:00 amRNSResearch confirms high performance of Parsortix
12th Jan 20217:00 amRNSChange of Auditor
5th Jan 20217:00 amRNSIssue of Equity
9th Dec 20207:00 amRNSParsortix can capture single cancer cell in sample
20th Nov 20204:18 pmRNSHolding(s) in Company
18th Nov 20204:51 pmRNSHolding(s) in Company
13th Nov 202010:46 amRNSResult of General Meeting
3rd Nov 20202:54 pmRNSDirector/PDMR Shareholding
29th Oct 20207:00 amRNSInterim Results
27th Oct 20206:28 pmRNSResult of Placing & Notice of General Meeting
27th Oct 20207:00 amRNSAccelerated bookbuild to raise up to £20m
20th Oct 20207:00 amRNSSubmission accepted by FDA for substantive review
28th Sep 20207:00 amRNSIssue of LTIP Options and Share Options
28th Sep 20207:00 amRNSANGLE announces completion of FDA submission
23rd Sep 20207:00 amRNSPotential treatment strategy to limit metastasis
11th Sep 20203:35 pmRNSHolding(s) in Company
11th Sep 20203:30 pmRNSHolding(s) in Company
2nd Sep 20201:49 pmRNSNotification of Interim Results and Webcast
2nd Sep 202010:00 amRNSHolding(s) in Company
27th Aug 20203:13 pmRNSResult of 2020 Annual General Meeting
18th Aug 20209:30 amRNSHolding(s) in Company
14th Aug 20207:00 amRNSParsortix use to assess response to immunotherapy
6th Aug 202012:20 pmRNSHolding(s) in Company
5th Aug 20207:00 amRNSNotice of AGM and Posting of Annual Report
20th Jul 20207:00 amRNSStudy: Parsortix use in metastatic breast cancer
8th Jul 20205:35 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
8th Jul 20205:30 pmRNSHolding(s) in Company
25th Jun 20207:00 amRNSPreliminary Results
22nd Jun 20207:00 amRNSBlood donations recommenced for FDA studies
29th May 20207:00 amRNSNotice of Results
12th May 20207:00 amRNSCTC potential as biomarker in MET inhibitor trials
4th May 20207:00 amRNSLeading cancer centre publishes Parsortix workflow
28th Apr 20207:00 amRNSBusiness Update
17th Apr 20207:00 amRNSParsortix performance in head and neck cancer
3rd Mar 20207:00 amRNSAssessing risk of brain metastasis in lung cancer
27th Feb 20207:00 amRNSParsortix outperforms other CTC systems in RCC
25th Feb 20207:00 amRNSANGLE announce Tri-Con presentation with BioView
17th Feb 20207:00 amRNSData demonstrates key advantages of Parsortix
11th Feb 20207:00 amRNSStudy demonstrates Parsortix potential in melanoma
3rd Feb 20209:10 amRNSIssue of Equity
30th Jan 20207:00 amRNSInterim Results
30th Jan 20207:00 amRNSChange of accounting reference date

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.